Scarica l'app Stockscreener
115.30
1.57%
-1.84
Dopo l'orario di chiusura:
115.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$117.14
Aprire:
$116.76
Volume 24 ore:
2.17M
Relative Volume:
1.35
Capitalizzazione di mercato:
$23.37B
Reddito:
$5.36B
Utile/perdita netta:
$1.43B
Rapporto P/E:
16.30
EPS:
7.0718
Flusso di cassa netto:
$1.42B
1 W Prestazione:
-6.93%
1M Prestazione:
-10.50%
6M Prestazione:
+20.19%
1 anno Prestazione:
+33.63%
Intervallo 1D:
$114.57
$117.19
Intervallo di 1 settimana:
$114.57
$126.14
Portata 52W:
$82.81
$132.60
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
115.30 | 25.11B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-02-05 | Iniziato | H.C. Wainwright | Buy |
| 2026-01-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance
INCY Maintained by Wells Fargo -- Price Target Raised to $128 - GuruFocus
Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating - marketscreener.com
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup - ChartMill
Incyte patents new VRK1 inhibitors - BioWorld News
Incyte Corp Lobbyists, 2019 - OpenSecrets
INCY Maintained by JP Morgan -- Price Target Raised to $123.00 - GuruFocus
INCY Maintained by HC Wainwright & Co. -- Price Target Raised to $152 - GuruFocus
H.C. Wainwright raises Incyte stock price target on Atebrioz approval By Investing.com - Investing.com Nigeria
A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Yahoo Finance
Incyte takes FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva - AllSci
JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating - marketscreener.com
Incyte Corporation (INCY) Stock Price Today: $123.89 - Pluang
Incyte Corp Lobbyists, 2025 - OpenSecrets
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
INCYTE CORP (INCY) Stock Chart - ChartMill
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Yahoo Finance
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
FDA Approves Atebrioz for Rare Bone Disorder, Boosting Incyte Co - GuruFocus
Form 4 Incyte Corporation For: 25 September By Investing.com - Investing.com Canada
Form 4 Incyte Corporation For: 25 September - Investing.com India
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share. - Stock Titan
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data - Yahoo Finance
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data - Yahoo Finance
Analysts Offer Insights on NA Companies: Incyte (INCY) and Coherent Corp (COHR) - theglobeandmail.com
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corporation (INCY) latest stock news and headlines - Yahoo Finance UK
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says - marketscreener.com
INCY Reiterated by RBC Capital -- Price Target Maintained at $10 - gurufocus.com
Incyte to present inflammation and autoimmunity data at EADV - Investing.com
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio - Business Wire
INCY Looks 18.6% Overvalued on GF Value™ as of September 2026 - GuruFocus
Incyte Expands Skin Diseases Treatment Partnership in Australia - marketscreener.com
Incyte stock heads into the open after a 1.8% pullback - AD HOC NEWS
Specialised Therapeutics expands Incyte partnership to Australia - Investing.com
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte stock gains institutional backing as Bank of America boosts position - AD HOC NEWS
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia - Yahoo Finance
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Yahoo Finance
What Is Incyte Corporation (NASDAQ:INCY) Signaling Through Its Pipeline? - Kalkine Media
Incyte stock gains as investors eye September FDA decision and pipeline catalysts - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum - ChartMill
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains? - Stocktwits
Incyte stock heads into the open after a 2.5% gain - AD HOC NEWS
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Incyte Corp Azioni (INCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | President, Global Head of R&D |
Sep 15 '26 |
Sale |
120.49 |
23,218 |
2,797,629 |
183,200 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):